Answers are grounded in this paper and cite their sources.
After decades of research and technology refinements and a couple of unfortunate setbacks, the recent trend of positive clinical results in the field of cell and gene therapy has been hailed as a triumph for this class of therapeutic. However, the lack of strong evidence for therapeutic effectiveness at market launch and high costs remain major hurdles to their routine clinical deployment, rendering these therapies possibly unaffordable for payers and inaccessible to society. This is already reality, given the withdrawal of several advanced therapies from the EU market due primarily to commercial failures.
No takes yet. Share an insight, caveat, or question.
Abou‐El‐Enein et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: